Home » Prices » NASDAQ:CLVS

Clovis Oncology, Inc. stock price

Today's NASDAQ:CLVS chart, history & news

Price:
4.76 USD
Change:
+0.32 (7.21%)
Key Stats
Price open 4.55
Previous close 4.44
Market cap 420.40M
Volume 4.49M
Day high 4.82
Day low 4.523
Year high 17.37
Year low 3.62
Year to date change -46.35%
P/E Ratio -0.91
Company Profile
Fundamentals
Insider Information
News

About Clovis Oncology, Inc.

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Company information

Company name
Clovis Oncology, Inc.
Exchange
Sector
Health Technology
Industry
Biotechnology
Employees
484
CEO
Patrick J. Mahaffy
Address
5500 Flatiron Parkway, Boulder, CO, 80301
Country
United States
Contact information
1.303.625.5000
Website
http://www.clovisoncology.com

Related companies

Invezz uses cookies to provide you with a great user experience. By using Invezz, you accept our privacy policy.